 Receptors, Opioid, mu
"Receptors, Opioid, mu" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine.
| Descriptor ID |
D017450
|
| MeSH Number(s) |
D12.776.543.750.695.620.550 D12.776.543.750.720.600.610.550 D12.776.543.750.750.555.610.550
|
| Concept/Terms |
Receptors, Opioid, mu- Receptors, Opioid, mu
- Opioid Receptors, mu
- mu Opioid Receptors
- Receptors, mu Opioid
- Receptors, mu
- mu Receptor
- Receptor, mu
- mu Receptors
- mu Opioid Receptor
- Opioid Receptor, mu
- Receptor, mu Opioid
Morphine Receptor- Morphine Receptor
- Receptor, Morphine
- Receptors, Morphine
- Morphine Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Opioid, mu".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Opioid [D12.776.543.750.695.620]
- Receptors, Opioid, mu [D12.776.543.750.695.620.550]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Opioid [D12.776.543.750.720.600.610]
- Receptors, Opioid, mu [D12.776.543.750.720.600.610.550]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Opioid [D12.776.543.750.750.555.610]
- Receptors, Opioid, mu [D12.776.543.750.750.555.610.550]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Opioid, mu".
This graph shows the total number of publications written about "Receptors, Opioid, mu" by people in this website by year, and whether "Receptors, Opioid, mu" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 3 | 4 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 1 | 1 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 2 | 4 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Opioid, mu" by people in Profiles.
-
McGovern DJ, Polter AM, Pr?vost ED, Ly A, McNulty CJ, Rubinstein B, Root DH. Ventral tegmental area glutamate neurons establish a mu-opioid receptor gated circuit to mesolimbic dopamine neurons and regulate opioid-seeking behavior. Neuropsychopharmacology. 2023 12; 48(13):1889-1900.
-
Bergum N, Berezin CT, King CM, Vigh J. ?-Opioid Receptors Expressed by Intrinsically Photosensitive Retinal Ganglion Cells Contribute to Morphine-Induced Behavioral Sensitization. Int J Mol Sci. 2022 Dec 14; 23(24).
-
Schacht JP, Hoffman M, Chen BH, Anton RF. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, M?ller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 10; 110(4):888-896.
-
Muscat SM, Deems NP, D'Angelo H, Kitt MM, Grace PM, Andersen ND, Silverman SN, Rice KC, Watkins LR, Maier SF, Barrientos RM. Postoperative cognitive dysfunction is made persistent with morphine treatment in aged rats. Neurobiol Aging. 2021 02; 98:214-224.
-
Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, Hoffman M, Schacht JP. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
-
Isaacs DP, Leman RP, Everett TJ, Lopez-Beltran H, Hamilton LR, Oleson EB. Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats. Neuropsychopharmacol Rep. 2020 12; 40(4):355-364.
-
Zhang XY, Li Q, Dong Y, Yan W, Song K, Lin YQ, Sun YG. Mu-Opioid Receptors Expressed in Glutamatergic Neurons are Essential for Morphine Withdrawal. Neurosci Bull. 2020 Oct; 36(10):1095-1106.
-
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
-
Ehringer MA. Identifying epigenetic targets underlying the effects of prenatal exposure to opioids. Genes Brain Behav. 2019 07; 18(6):e12503.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|